The Indian arm of multinational drug-maker Mylan NV has launched its generic version of Hepatitic C drug sofosbuvir in the country, under the brand name MyHep, the company said, without divulging its price.
The once-a-day pill, originally from Gilead Sciences, has been in the eye of a storm in India and overseas over its pricing.
And Mylan’s launch will further stir the pot of generic competition on the drug.
Gilead’s sofosbuvir is priced at $84,000 for 12 weeks and its representatives have in the past told BusinessLine that the drug would be pegged in India at about $900 for the same period. Gilead’s patent application in India on the drug is also in a critical position, with one application being already rejected, even as another is pending at the Kolkata Patent Office.